Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Other hematologic neoplasm 3Lymphoid 2Breast 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Endometrial Clear Cell Adenocarcinoma 1

Interventions

Doxorubicin 40Radiotherapy 30Ifosfamide 28Vincristine 27Cyclophosphamide 24Imatinib Mesylate 20Etoposide 20Dactinomycin 14Radiation 13Filgrastim 11Temozolomide 9Sunitinib 9Trabectedin 8Methotrexate 8Specimen Handling 7Magnetic Resonance Spectroscopy 6Granulocyte Colony-Stimulating Factor 6Chemotherapy, Adjuvant 6pazopanib 5nilotinib 5Zoledronic Acid 5Neoadjuvant Therapy 5Irinotecan 5Cisplatin 5Carboplatin 5X-Rays 4Vinorelbine 4Topotecan 4Surgical Procedures, Operative 4Procarbazine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Practice Guidelines as Topic × Sarcoma × Clear all
NCT03422198 2025-12-12

SAVE

University of Utah

Phase 3 Recruiting
188 enrolled 15 charts
GynecologicSarcoma

Endometrial Clear Cell Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡